Edition:
United Kingdom

argenx NV (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

48.39EUR
15 Dec 2017
Change (% chg)

€-5.11 (-9.55%)
Prev Close
€53.50
Open
€50.94
Day's High
€50.94
Day's Low
€45.06
Volume
192,172
Avg. Vol
41,761
52-wk High
€57.48
52-wk Low
€14.55

Chart for

About

argenx NV, formerly arGEN X BV is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

Beta: --
Market Cap(Mil.): €583.54
Shares Outstanding(Mil.): 26.89
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS

13 Dec 2017

BRIEF-Argenx announces launch of proposed public offering in United States

* ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES

11 Dec 2017

BRIEF-Argenx Files For Offering Of Up To $150 Mln American Depositary Shares

* ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING Source text: (http://bit.ly/2kmUxUi) Further company coverage:

11 Dec 2017

BRIEF-Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110

* TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Dec 2017

BRIEF-Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113

* REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113

11 Dec 2017

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​

30 Oct 2017

BRIEF-Argenx 9M total comprehensive loss widens to 16.5 million euros

* REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

26 Oct 2017

BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris

* ARGENX LAUNCHES PHASE II PROOF-OF-CONCEPT CLINICAL TRIAL OF ARGX-113 FOR THE TREATMENT OF PEMPHIGUS VULGARIS

26 Sep 2017

BRIEF-Argenx reaches 50% enrollment in phase 2 clinical trial of ARGX-113

* REG-ARGENX REACHES 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF ARGX-113 IN IMMUNE THROMBOCYTOPENIA

20 Sep 2017

BRIEF-ArgenX cash and cash equivalents at end H1 stood at 173.4 million euros

* H1 LOSS BEFORE TAXES EUR 7.6 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO

24 Aug 2017

Earnings vs. Estimates